SCHEMBL5134969

SCHEMBL5134969

CCCCN(Cc1ccc(Br)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.41
ATP4A P20648 3/20 0.39
ATP4B P51164 3/20 0.39
CRHR1 P34998 2/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
HDAC1 Q13547 1/20 0.38
MAPT P10636 1/20 0.37
TSHR P16473 3/20 0.37
HSD11B1 P28845 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 2/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
BCHE P06276 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136527 0.96 C5AR1 (0.46) C5AR1ATP4AATP4BCRHR1PPARG
SCHEMBL5137501 0.95 C5AR1 (0.43) C5AR1ATP4AATP4BCRHR1PPARG
SCHEMBL5134816 0.92 CRHR1 (0.44) C5AR1ATP4AATP4BCRHR1HDAC1
SCHEMBL5135043 0.92 C5AR1 (0.46) C5AR1CRHR1PPARGPPARATSHR
SCHEMBL5135456 0.92 C5AR1 (0.43) C5AR1ATP4AATP4BCRHR1HDAC1
SCHEMBL5135599 0.92 C5AR1 (0.43) C5AR1ATP4AATP4BCRHR1HDAC1
SCHEMBL5136269 0.90 CRHR1 (0.42) C5AR1ATP4AATP4BCRHR1TSHR
SCHEMBL5136813 0.90 C5AR1 (0.41) C5AR1ATP4AATP4BCRHR1TSHR
SCHEMBL5134997 0.89 C5AR1 (0.47) C5AR1TSHRHSD11B1KDM4EALDH1A1
SCHEMBL5072228 0.88 C5AR1 (0.46) C5AR1HDAC1TSHRHSD11B1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed